DIMERx Secures Global Rights to a Novel Amino Acid Prodrug Dimer Developed at Massachusetts General Hospital
May 22 2024 - 8:35AM
Business Wire
- Company to Pursue Applications in Rare Diseases and Proprietary
Medical Food Domains
- Deal Unlocks Opportunities for Future Collaborations
DIMERx, Inc., an advance-stage biopharmaceutical company,
announced today that it has secured rights from Massachusetts
General Hospital (MGH) for a novel amino acid dimer to be developed
for two rare disease indications in the U.S. and as a proprietary
medical food for ex-U.S. markets. This exclusive patent license
agreement marks a pivotal step in harnessing the therapeutic
potential of amino acids as drugs. Through this strategic
collaboration, DIMERx aims to challenge treatment paradigms across
multiple health conditions.
The dimer, developed and patented by Maurizio Fava, M.D., Chair
of Psychiatry at MGH, and by Xudong Huang, Ph.D., Co-Director of
the Neurochemistry Lab of the MGH Department of Psychiatry,
presents vast therapeutical potential and the company is excited to
bring the groundbreaking molecule to patients. “I am delighted that
DIMERx and MGH have entered into this agreement,” stated Dr. Fava.
“DIMERx has been on the forefront of harnessing therapeutic
potential of compounds with covalent bonds through dimerization.
The company has a strong scientific foundation within the small
molecule modality and has visionary leadership. DIMERx is the right
partner, and we are looking forward to advancing the dimer from
paper to patients.”
Co-founders Nikhilesh Singh, M.Pharm., Ph.D., Chief Executive
Officer, and Gregory Beyer, Chief Financial Officer of DIMERx,
expressed enthusiasm about the transformative potential of the
compound. Dr. Singh stated, “This significant milestone marks a
pivotal moment for DIMERx, and we are incredibly grateful to Dr.
Fava for the opportunity to collaborate with him and one of the
premier research institutes in the world.”
About DIMERx, Inc.
DIMERx is a clinical-stage biopharmaceutical company focused on
the development of a novel platform of first-in-class dimer
therapeutics. The company’s lead asset, DMX-101, has demonstrated
safety, tolerability, and effectiveness in controlling abdominal
pain and GI motility in a Phase 2 study. DIMERx is currently
evaluating financing options that align with the company’s vision
of establishing itself as a transformative drug company within the
small molecule dimer space.
Forward-Looking Statements
This press release contains “forward-looking statements,” which
reflect our current views and expectations with respect to future
outcomes or events. When used in this press release, the words
“could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,”
“project” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain such identifying words. Because these statements
are based on current estimates and assumptions, they are inherently
subject to risks that could cause the actual outcomes to differ
materially from what we currently expect. These forward-looking
statements are subject to numerous risks and uncertainties,
including, among others, the facts that we are substantially
dependent on our ability to successfully develop and commercialize
our products; the commercial adoption of our products and any other
product candidates we develop will depend on the degree of their
market acceptance; we have only limited assets and will need to
raise additional capital before we can expect to generate revenue
or become profitable; and we have never generated any revenue and
may never be profitable. Forward-looking statements in this
presentation apply only as of the date made, and we undertake no
obligation to update or revise any forward-looking statements to
reflect subsequent events or circumstances.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522736445/en/
Gregory Beyer Chief Financial Officer investors@dimerx.com